Proprotein convertase subtilisin kexin 9 inhibitors: Current status and future directions

Proprotein convertase subtilisin kexin 9 inhibitors: Current status and future directions

The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces low-density lipoprotein receptor (LDLR) recycling, leading to a decrease of LDL cholesterol (LDL-C) receptors on the surface of hepatocyt...

Full description

Bibliographic Details
Main Authors: JPS Sawhney, Saurabh Bagga
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Journal of Clinical and Preventive Cardiology
Subjects:
Dyslipidemia
familial hypercholesterolemia
statin intolerance
Online Access:http://www.jcpconline.org/article.asp?issn=2250-3528;year=2017;volume=6;issue=1;spage=12;epage=17;aulast=Sawhney

Similar Items

Similar Items